{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:12:18Z","timestamp":1703722338713},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World j. surg."],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The selection of patients with axillary lymph node\u2010negative breast cancer who should receive adjuvant therapy today is confused by an expanding arsenal of putative prognostic factors. The size of the primary tumor remains the dominant factor in sorting among this group of patients, with general agreement that tumors 1\u00a0cm or less should be spared adjuvant systemic therapy outside of a clinical trial. There are a few favorable histologic subgroups that may be added to this excluded group: ductal carcinoma in situ and pure tubular, papillary, and typical medullary tumors. For the larger tumor (generally &gt;2\u00a0cm in diameter, but always &gt;3\u00a0cm), there is little disagreement that adjuvant therapy is indicated. The host of additional prognostic factors are directed mainly toward the group of tumors that fall between these two categories. Nuclear grade, S\u2010phase, and perhaps p53\u00a0mutations influence decisions for treatment by their elevation. Although the decision remains with the patient and the recommendation with the mature judgment of the clinician, the prognostic indicators available continue to multiply. That an indicator can retrospectively sort prognosis is of limited interest. It requires prospective validation in another patient population, reproducibility in other laboratories, and multivariate analysis among factors measured on the same population of patients to integrate a factor into clinical decision\u2010making. It is only beginning to be accomplished. The next generation of factors being sought are those that predict for response or lack or response to specific therapies, rather than merely indicating natural history. Estrogen and progesterone receptors are the prototypes of this class of indicators.<\/jats:p>","DOI":"10.1007\/bf00348190","type":"journal-article","created":{"date-parts":[[2004,12,10]],"date-time":"2004-12-10T07:37:32Z","timestamp":1102664252000},"page":"39-44","source":"Crossref","is-referenced-by-count":10,"title":["Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node\u2010negative breast cancer patients"],"prefix":"10.1002","volume":"18","author":[{"given":"William C.","family":"Wood","sequence":"first","affiliation":[{"name":"Department of Surgery Emory University School of Medicine 1364 Clifton Road N.E. 30322 Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1994,1]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90997-H"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460030097037"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410010086007"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206253262607"},{"key":"e_1_2_1_6_1","first-page":"79","article-title":"Number of lymph nodes examined and prognosis of breast carcinoma","volume":"131","author":"Fisher B.","year":"1970","journal-title":"Surg. Gynecol. Obstet."},{"key":"e_1_2_1_7_1","first-page":"163","article-title":"Classical prognostic factors in node\u2010negative breast cancer: the DBCG experience","volume":"11","author":"Mouridsen H.T.","year":"1992","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1239"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.1.83"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H"},{"key":"e_1_2_1_11_1","first-page":"169","volume-title":"Adjuvant Therapy of Cancer VI","author":"Mansour E.G.","year":"1990"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1239"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.7.1076"},{"issue":"34","key":"e_1_2_1_14_1","article-title":"Tumor necrosis is a histoprognosticator for early recurrence and death in stage II breast cancer [abstract]","volume":"58","author":"Gilchrist K.","year":"1988","journal-title":"Lab. Invest."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.12.1006"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30524-0"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-198807000-00011"},{"key":"e_1_2_1_18_1","first-page":"1052","article-title":"Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods","volume":"49","author":"Kinsel L.B.","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_1_19_1","first-page":"39","article-title":"Estrogen receptor immunocytochemical assay in paraffin embedded tissue: a better gold standard?","volume":"1","author":"Battifora H.","year":"1993","journal-title":"Appl. Immunohistochem."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(90)90013-J"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901015)66:8<1663::AID-CNCR2820660802>3.0.CO;2-C"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1990.01410130113018"},{"key":"e_1_2_1_23_1","first-page":"167","article-title":"Preliminary analysis: the impact of DNA flow cytometry measurements to predict time to recurrence in the intergroups (INT 011) node negative clinical trial: an Eastern Cooperative Oncology Group study","volume":"11","author":"Dressler L.G.","year":"1992","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"e_1_2_1_24_1","unstructured":"Mansour E.G. Ravdin P.M. Dressler L.:Prognostic factors in early breast carcinoma. in press."},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90421-8"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.12.965"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.3.200"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.11.845"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01660975"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240101"},{"key":"e_1_2_1_31_1","first-page":"67","article-title":"Angiogenesis does not predict recurrence in patients with primary breast cancer","volume":"12","author":"Khanuja P.S.","year":"1993","journal-title":"Proc. ASCO"},{"key":"e_1_2_1_32_1","unstructured":"Grondahl\u2010Hansen J. Thorpe S.M. Rosenquist C. Christensen I.J. Rasmussen B.B. Pyke C.:High levels of u\u2010PA and PAI\u20101 in cytosols from breast cancer tissue are associated with poor prognosis. Presented at the 3rd International Workshop on the Molecular and Cellular Biology of Plasminogen Activation Elsinore May 8\u201313 1991."},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1002624"},{"key":"e_1_2_1_34_1","unstructured":"Wood W.C. Budman D.R. Korzun A.H. et al.:Dose and dose intensity trial of adjuvant chemotherapy for stage II node positive breast carcinoma. N. Engl. J. Med. (in press)."}],"container-title":["World Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00348190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00348190\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/BF00348190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T18:55:12Z","timestamp":1703703312000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1007\/BF00348190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1007\/BF00348190"],"URL":"https:\/\/doi.org\/10.1007\/bf00348190","archive":["Portico"],"relation":{},"ISSN":["0364-2313","1432-2323"],"issn-type":[{"value":"0364-2313","type":"print"},{"value":"1432-2323","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}